BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 1-Year High at $8.75

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares reached a new 52-week high during trading on Thursday . The company traded as high as $8.75 and last traded at $8.74, with a volume of 316452 shares changing hands. The stock had previously closed at $8.55.

Analyst Ratings Changes

A number of research firms have recently commented on BCRX. Barclays increased their price objective on BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a report on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Finally, StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $14.17.

BioCryst Pharmaceuticals Trading Up 1.4 %

The business has a 50 day moving average of $7.23 and a 200-day moving average of $6.07. The stock has a market cap of $1.79 billion, a PE ratio of -8.16 and a beta of 1.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.11. The firm had revenue of $109.30 million for the quarter, compared to analysts’ expectations of $98.30 million. The company’s quarterly revenue was up 34.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.24) EPS. Research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.65 EPS for the current fiscal year.

Insiders Place Their Bets

In other BioCryst Pharmaceuticals news, Director Amy E. Mckee sold 8,600 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $6.32, for a total transaction of $54,352.00. Following the completion of the sale, the director now directly owns 27,831 shares of the company’s stock, valued at approximately $175,891.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Amy E. Mckee sold 8,600 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $6.32, for a total value of $54,352.00. Following the completion of the sale, the director now directly owns 27,831 shares of the company’s stock, valued at approximately $175,891.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Machelle Sanders sold 4,689 shares of the firm’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $6.00, for a total value of $28,134.00. Following the transaction, the director now directly owns 27,742 shares of the company’s stock, valued at approximately $166,452. The disclosure for this sale can be found here. 4.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 15.4% during the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock worth $106,405,000 after purchasing an additional 2,371,401 shares in the last quarter. Norges Bank acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $13,278,000. Rafferty Asset Management LLC lifted its stake in shares of BioCryst Pharmaceuticals by 18.3% during the fourth quarter. Rafferty Asset Management LLC now owns 955,587 shares of the biotechnology company’s stock worth $5,724,000 after purchasing an additional 147,699 shares in the last quarter. ProShare Advisors LLC lifted its stake in shares of BioCryst Pharmaceuticals by 9.1% during the first quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 4,041 shares in the last quarter. Finally, Braidwell LP lifted its stake in shares of BioCryst Pharmaceuticals by 6.6% during the fourth quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock worth $34,254,000 after purchasing an additional 355,497 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.